Andrew Dudum; Chairman of the Board, Chief Executive Officer; Hims & Hers Health Inc Oluyemi Okupe; Chief Financial Officer; Hims & Hers Health Inc Good afternoon, ladies and gentlemen, and thank you ...

Q4 2024 Earnings Call Transcript February 24, 2025 Hims & Hers Health, Inc. beats earnings expectations. Reported EPS is $0.11, expectations were $0.09. Operator: Good afternoon, ladies and gentlemen, ...

Shares of Hims & Hers Health tumbled 18% premarket on Tuesday as Wall Street analysts questioned the telehealth provider's ...

Investing.com - Hims&Hers (NYSE:HIMS) said on Monday that it may stop selling legal copies of a popular weight-loss drug made by Denmark's Novo Nordisk (NYSE:NVO), sending shares in the U.S.

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...

A series of important developments in the healthcare sector includes Medtronic adapting to tariff threats, Hims & Hers facing ...

Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) will be reporting earnings tomorrow after the bell. Here’s ...

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...

Ahead of whatever Jensen Huang & Co. announces, let's look at another highflying stock: Costco Wholesale (COST). Christopher Bloomstran, the president and chief investment officer St. Louis-based ...

Hims is pivoting after drugmaker Novo Nordisk on Friday said the Food and Drug Administration has determined that the shortage of Wegovy and Ozempic has been resolved. Compounding its challenges in ...

The telehealth company Hims & Hers has made waves for its Super Bowl ad that plugged its lower-priced form of injectable ...

Citi raised the firm’s price target on Hims & Hers to $27 from $25 and keeps a Sell rating on the shares post the Q4 report. The focus on ...